首页 > 最新文献

Journal of Immunotherapy最新文献

英文 中文
Survival Impact of Inflammation-based Prognostic Scores in Metastatic or Unresectable Esophageal Cancer Treated With Pembrolizumab Plus Chemotherapy. 基于炎症的预后评分对使用 Pembrolizumab 加化疗治疗的转移性或无法切除的食管癌患者生存期的影响
IF 3.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-09-01 Epub Date: 2024-06-03 DOI: 10.1097/CJI.0000000000000529
Takahito Sugase, Takashi Kanemura, Tomohira Takeoka, Norihiro Matsuura, Yasunori Masuike, Naoki Shinno, Hisashi Hara, Masatoshi Kitakaze, Masahiko Kubo, Yosuke Mukai, Toshinori Sueda, Shinichiro Hasegawa, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata

Pembrolizumab plus chemotherapy has been indicated as the first-line treatment for metastatic or unresectable locally advanced esophageal cancer. However, pretreatment biomarkers for predicting clinical outcomes remain unclear. We investigated the predictive value of inflammation-based prognostic scores in patients treated with pembrolizumab and chemotherapy. The Prognostic Nutritional Index (PNI), C-reactive protein/albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were calculated before initial treatment in 65 eligible patients with metastatic or unresectable locally advanced esophageal cancer receiving pembrolizumab plus CF therapy, and the relationship between these biomarkers and clinical outcomes was analyzed. The objective response rate (ORR) and progression disease (PD) were observed in 51% and 21% of all patients. Patients with PNI<39 have significantly worse treatment responses than those with PNI≥39 (ORR; 28% vs. 60%, PD; 44% vs. 13%, P =0.020). Progression-free survival (PFS) is significantly associated with the PNI and CAR ( P <0.001 and P =0.004, respectively). Overall survival (OS) is associated with PNI, CAR, and PLR ( P <0.001, P =0.008, and P =0.018, respectively). The PNI cutoff value of 39 is identified as an independent factor for PFS (odds ratio=0.27, 95% CI: 0.18-0.81, P =0.012) and OS (odds ratio=0.22, 95% CI: 0.08-0.59, P =0.003). Patients with PNI<39 have significantly worse 6-month PFS and 1-year OS than those with PNI≥39 (27.8% vs. 66.7%, 27.2% vs. 81.1%, respectively). In conclusion, inflammation-based prognostic scores are associated with survival in patients treated with pembrolizumab plus CF therapy. Pretreatment PNI is a promising candidate for predicting treatment response and survival.

Pembrolizumab 联合化疗已被列为转移性或无法切除的局部晚期食管癌的一线治疗方法。然而,预测临床结果的预处理生物标志物仍不明确。我们研究了基于炎症的预后评分对接受彭博利珠单抗和化疗患者的预测价值。我们在65名接受pembrolizumab加CF治疗的符合条件的转移性或无法切除的局部晚期食管癌患者的初始治疗前计算了预后营养指数(PNI)、C反应蛋白/白蛋白比值(CAR)、中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR),并分析了这些生物标志物与临床预后之间的关系。在所有患者中,分别有51%和21%的患者观察到了客观反应率(ORR)和疾病进展(PD)。PNI患者
{"title":"Survival Impact of Inflammation-based Prognostic Scores in Metastatic or Unresectable Esophageal Cancer Treated With Pembrolizumab Plus Chemotherapy.","authors":"Takahito Sugase, Takashi Kanemura, Tomohira Takeoka, Norihiro Matsuura, Yasunori Masuike, Naoki Shinno, Hisashi Hara, Masatoshi Kitakaze, Masahiko Kubo, Yosuke Mukai, Toshinori Sueda, Shinichiro Hasegawa, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata","doi":"10.1097/CJI.0000000000000529","DOIUrl":"10.1097/CJI.0000000000000529","url":null,"abstract":"<p><p>Pembrolizumab plus chemotherapy has been indicated as the first-line treatment for metastatic or unresectable locally advanced esophageal cancer. However, pretreatment biomarkers for predicting clinical outcomes remain unclear. We investigated the predictive value of inflammation-based prognostic scores in patients treated with pembrolizumab and chemotherapy. The Prognostic Nutritional Index (PNI), C-reactive protein/albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were calculated before initial treatment in 65 eligible patients with metastatic or unresectable locally advanced esophageal cancer receiving pembrolizumab plus CF therapy, and the relationship between these biomarkers and clinical outcomes was analyzed. The objective response rate (ORR) and progression disease (PD) were observed in 51% and 21% of all patients. Patients with PNI<39 have significantly worse treatment responses than those with PNI≥39 (ORR; 28% vs. 60%, PD; 44% vs. 13%, P =0.020). Progression-free survival (PFS) is significantly associated with the PNI and CAR ( P <0.001 and P =0.004, respectively). Overall survival (OS) is associated with PNI, CAR, and PLR ( P <0.001, P =0.008, and P =0.018, respectively). The PNI cutoff value of 39 is identified as an independent factor for PFS (odds ratio=0.27, 95% CI: 0.18-0.81, P =0.012) and OS (odds ratio=0.22, 95% CI: 0.08-0.59, P =0.003). Patients with PNI<39 have significantly worse 6-month PFS and 1-year OS than those with PNI≥39 (27.8% vs. 66.7%, 27.2% vs. 81.1%, respectively). In conclusion, inflammation-based prognostic scores are associated with survival in patients treated with pembrolizumab plus CF therapy. Pretreatment PNI is a promising candidate for predicting treatment response and survival.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"249-257"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
False-positive Findings of Large Vessel Vasculitis on FDG-PET in Patients Treated With Immune Checkpoint Inhibitors. 免疫检查点抑制剂治疗患者的 FDG-PET 大血管炎假阳性发现
IF 3.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-20 DOI: 10.1097/CJI.0000000000000527
Dylan Johnson, Shahin Jamal, Ryan W Hung, Carrie Ye

Fluorine-18 fluorodeoxygluocose positron emission tomography (FDG-PET) is increasingly used in the evaluation of response to immune checkpoint inhibitor (ICI) therapy. Incidental findings of increased vessel wall uptake may prompt the concern for ICI-induced large vessel vasculitis (LVV). Precise radiographic and clinical evaluation is required to determine if this represents true vasculitis, as use of immune suppression and ICI discontinuation can have significant impacts on patient outcomes. We performed a retrospective case analysis of 4 consecutive patients referred to 2 rheumatology clinics treated with ICI with incidental findings of LVV on FDG-PET, reviewing their clinical course and radiographic findings. All 4 cases had FDG-PET scans for routine oncology indications and had no associated clinical features of LVV. One patient was treated with corticosteroids and no patients developed any clinical evidence of vasculitis during a mean follow-up period of 17 months (range: 7-33 mo). All FDG-PET images reporting LVV underwent a standardized analysis to identify any technical issues or concerns with interpretation. In review of imaging, 3 of the cases may have been due to delayed tracer to scan interval leading to misinterpretation of vascular uptake as suspected LVV. Recognition of technical pitfalls in FDG-PET interpretation is crucial to inform the need for immunosuppression and the safety of continued ICI therapy.

氟-18-脱氧葡萄糖正电子发射断层扫描(FDG-PET)越来越多地用于评估免疫检查点抑制剂(ICI)疗法的反应。偶然发现的血管壁摄取增加可能会引发对 ICI 诱导的大血管炎(LVV)的担忧。由于使用免疫抑制剂和停用 ICI 会对患者预后产生重大影响,因此需要进行精确的放射学和临床评估,以确定这是否代表真正的血管炎。我们对转诊至两家风湿病诊所接受 ICI 治疗并在 FDG-PET 上偶然发现 LVV 的 4 例连续患者进行了回顾性病例分析,回顾了他们的临床病程和影像学检查结果。这4例患者都是因常规肿瘤适应症而进行FDG-PET扫描,没有相关的左心室静脉瘤临床特征。一名患者接受了皮质类固醇治疗,在平均 17 个月(7-33 个月)的随访期间,没有患者出现任何血管炎的临床症状。所有报告左心室积液的 FDG-PET 图像都经过了标准化分析,以确定任何技术问题或解释问题。在对成像进行复查时,有 3 例病例可能是由于示踪剂与扫描时间间隔延迟,导致血管摄取被误认为是疑似左心室变性。识别 FDG-PET 解读中的技术误区对于确定免疫抑制的必要性和继续 ICI 治疗的安全性至关重要。
{"title":"False-positive Findings of Large Vessel Vasculitis on FDG-PET in Patients Treated With Immune Checkpoint Inhibitors.","authors":"Dylan Johnson, Shahin Jamal, Ryan W Hung, Carrie Ye","doi":"10.1097/CJI.0000000000000527","DOIUrl":"10.1097/CJI.0000000000000527","url":null,"abstract":"<p><p>Fluorine-18 fluorodeoxygluocose positron emission tomography (FDG-PET) is increasingly used in the evaluation of response to immune checkpoint inhibitor (ICI) therapy. Incidental findings of increased vessel wall uptake may prompt the concern for ICI-induced large vessel vasculitis (LVV). Precise radiographic and clinical evaluation is required to determine if this represents true vasculitis, as use of immune suppression and ICI discontinuation can have significant impacts on patient outcomes. We performed a retrospective case analysis of 4 consecutive patients referred to 2 rheumatology clinics treated with ICI with incidental findings of LVV on FDG-PET, reviewing their clinical course and radiographic findings. All 4 cases had FDG-PET scans for routine oncology indications and had no associated clinical features of LVV. One patient was treated with corticosteroids and no patients developed any clinical evidence of vasculitis during a mean follow-up period of 17 months (range: 7-33 mo). All FDG-PET images reporting LVV underwent a standardized analysis to identify any technical issues or concerns with interpretation. In review of imaging, 3 of the cases may have been due to delayed tracer to scan interval leading to misinterpretation of vascular uptake as suspected LVV. Recognition of technical pitfalls in FDG-PET interpretation is crucial to inform the need for immunosuppression and the safety of continued ICI therapy.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"275-278"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma. Nivolumab是治疗转移性唾液腺导管癌的一种很有前途的方法。
IF 3.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-28 DOI: 10.1097/CJI.0000000000000513
Luis Bugia, Frederic Jungbauer, Lena Zaubitzer, Christian Hörner, Kirsten Merx, Abo-Madyan Yasser, Thomas Germann, Anne Lammert, Claudia Scherl, Nicole Rotter, Annette Affolter

Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.

腮腺唾液腺导管癌(SDC)是一种罕见的高度恶性肿瘤。一名 65 岁的男子出现耳前肿块。经过手术治疗和组织学检查,结果被解释为腮腺鳞状细胞癌(SCC)转移瘤,来源于原发性不明的腮腺原发性 SCC。患者接受了以铂为基础的辅助放化疗。然而,重新分期后发现了多个大小呈进行性发展的肺圆形病灶。在对肺部肿块进行切除和组织学检查并与原发肿瘤进行对比后,最初的 SCC 诊断被修改为腮腺 SDC。由于患者的 HER-2 状态为阳性,在一次个体治疗尝试中,患者接受了标签外曲妥珠单抗/多西他赛治疗,在此期间,肺转移灶出现了明显的进展。因此,患者根据其 PD-L1 阴性状态接受了 nivolumab 免疫疗法。经过 57 个周期的尼夫单抗治疗后,患者病情得到部分缓解,目前状况良好。我们首次报道了转移性 SDC 对使用 nivolumab 的检查点抑制剂的强效反应,而无需额外的放疗。
{"title":"Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.","authors":"Luis Bugia, Frederic Jungbauer, Lena Zaubitzer, Christian Hörner, Kirsten Merx, Abo-Madyan Yasser, Thomas Germann, Anne Lammert, Claudia Scherl, Nicole Rotter, Annette Affolter","doi":"10.1097/CJI.0000000000000513","DOIUrl":"10.1097/CJI.0000000000000513","url":null,"abstract":"<p><p>Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"258-262"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer. 用于预测乳腺癌预后和免疫疗法的 M2 类肿瘤相关巨噬细胞的综合分子分析。
IF 3.9 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-07-01 Epub Date: 2024-04-30 DOI: 10.1097/CJI.0000000000000517
Kexin Chang, QingFang Yue, Long Jin, Pengyu Fan, Yi Liu, Fei Cao, Yuan Zhang

The involvement of M2-like tumor-associated macrophages (TAMs) in the advancement and treatment of cancer has been widely documented. This study aimed to develop a new signature associated with M2-like TAMs to predict the prognosis and treatment response in individuals diagnosed with breast cancer (BC). Weighted gene co-expression network analysis (WGCNA) was used to identity for M2-like TAM-related modular genes. The M2-like TAM-related modular subtype was identified using unsupervised clustering. WGCNA identified 722 M2-like TAM genes, 204 of which were associated with recurrence-free survival (RFS). Patients in cluster 1 exhibited upregulated cancer-related pathways, a higher proportion of triple-negative breast cancer (TNBC) subtypes, lower expression of immune checkpoints, and worse prognosis. Cluster 2 was characterized by upregulated immune-related pathways, a higher proportion of luminal A subtypes, and higher expression of immune checkpoints. A prognostic signature was created and confirmed using an independent dataset. A well-built nomogram can accurately forecast the survival outcomes for every individual. Furthermore, patients classified as low-risk exhibited a more favorable outlook, elevated tumor microenvironment (TME) score, and superior reaction to immunotherapy. In conclusion, we discovered 2 different types of M2-like TAMs and developed a prognostic signature revealing the diversity of M2-like TAMs in BC and their correlation with immune status and prognosis. This feature can predict the prognosis and immunotherapeutic effects of BC and offer novel concepts and approaches for tailoring BC treatment.

M2样肿瘤相关巨噬细胞(TAMs)参与癌症的发展和治疗已被广泛记录。本研究旨在开发一种与M2样肿瘤相关巨噬细胞相关的新特征,以预测乳腺癌(BC)患者的预后和治疗反应。研究采用加权基因共表达网络分析(WGCNA)来识别与M2样TAM相关的模块基因。通过无监督聚类确定了M2样TAM相关模块亚型。WGCNA 确定了 722 个 M2-like TAM 基因,其中 204 个基因与无复发生存率(RFS)相关。群组1的患者表现出癌症相关通路上调、三阴性乳腺癌(TNBC)亚型比例较高、免疫检查点表达较低以及预后较差等特征。群组2的特点是免疫相关通路上调、管腔A亚型比例较高以及免疫检查点表达较高。我们创建了一个预后特征,并通过一个独立的数据集进行了确认。建立良好的提名图可以准确预测每个人的生存结果。此外,被归类为低风险的患者前景更乐观,肿瘤微环境(TME)评分更高,对免疫疗法的反应更佳。总之,我们发现了两种不同类型的M2样TAMs,并建立了一个预后特征,揭示了M2样TAMs在BC中的多样性及其与免疫状态和预后的相关性。这一特征可以预测 BC 的预后和免疫治疗效果,并为定制 BC 治疗提供了新的概念和方法。
{"title":"Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer.","authors":"Kexin Chang, QingFang Yue, Long Jin, Pengyu Fan, Yi Liu, Fei Cao, Yuan Zhang","doi":"10.1097/CJI.0000000000000517","DOIUrl":"10.1097/CJI.0000000000000517","url":null,"abstract":"<p><p>The involvement of M2-like tumor-associated macrophages (TAMs) in the advancement and treatment of cancer has been widely documented. This study aimed to develop a new signature associated with M2-like TAMs to predict the prognosis and treatment response in individuals diagnosed with breast cancer (BC). Weighted gene co-expression network analysis (WGCNA) was used to identity for M2-like TAM-related modular genes. The M2-like TAM-related modular subtype was identified using unsupervised clustering. WGCNA identified 722 M2-like TAM genes, 204 of which were associated with recurrence-free survival (RFS). Patients in cluster 1 exhibited upregulated cancer-related pathways, a higher proportion of triple-negative breast cancer (TNBC) subtypes, lower expression of immune checkpoints, and worse prognosis. Cluster 2 was characterized by upregulated immune-related pathways, a higher proportion of luminal A subtypes, and higher expression of immune checkpoints. A prognostic signature was created and confirmed using an independent dataset. A well-built nomogram can accurately forecast the survival outcomes for every individual. Furthermore, patients classified as low-risk exhibited a more favorable outlook, elevated tumor microenvironment (TME) score, and superior reaction to immunotherapy. In conclusion, we discovered 2 different types of M2-like TAMs and developed a prognostic signature revealing the diversity of M2-like TAMs in BC and their correlation with immune status and prognosis. This feature can predict the prognosis and immunotherapeutic effects of BC and offer novel concepts and approaches for tailoring BC treatment.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"205-215"},"PeriodicalIF":3.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Life-Saving Response to Anti-PD-1 in a Solid Organ Transplant Recipient With Metastatic Cutaneous Squamous Cell Carcinoma: A Case Report and Review. 一名转移性皮肤鳞状细胞癌实体器官移植受者对抗PD-1的快速救命反应:病例报告与综述
IF 3.9 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-27 DOI: 10.1097/CJI.0000000000000514
John P Antonelli, Myiah Quach, Aparna Mahajan, Jennifer Pleva, Vincent T Ma

Summary: Anti-programmed cell death protein 1 (PD-1) therapy is considered effective in the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma but the use of these agents in solid organ transplant recipients (SOTRs) is often taken with caution. While anti-tumor effects without graft rejection have been reported, studies have shown high rates of fatal graft rejection with immune checkpoint therapy. In this case report, we present an SOTR patient with life-threatening, acute hypoxic respiratory failure due to rapidly progressive metastatic cutaneous squamous cell carcinoma with lung and pleural involvement. Modification of their immunosuppressive regimen and treatment with front-line anti-PD-1 inhibitor, pembrolizumab, led to rapid clinical response with near complete resolution of metastatic pulmonary disease and no long-term evidence of graft rejection. Our case report shows that front-line treatment with PD-1 inhibitors can be safely administered in SOTR patients with rapid metastatic disease control.

摘要:抗程序性细胞死亡蛋白1(PD-1)疗法被认为是治疗转移性或局部晚期皮肤鳞状细胞癌的有效方法,但在实体器官移植受者(SOTR)中使用这些药物往往需要谨慎。虽然有报道称免疫检查点疗法具有抗肿瘤效果,但不会出现移植物排斥反应,而研究显示免疫检查点疗法的致命性移植物排斥反应发生率很高。在本病例报告中,我们介绍了一名因快速进展的转移性皮肤鳞状细胞癌并累及肺部和胸膜而出现急性缺氧性呼吸衰竭、危及生命的 SOTR 患者。修改免疫抑制方案并使用一线抗PD-1抑制剂pembrolizumab治疗后,患者的临床反应迅速,转移性肺部疾病几乎完全缓解,且没有长期的移植物排斥证据。我们的病例报告表明,SOTR 患者可以安全地使用 PD-1 抑制剂进行一线治疗,并迅速控制转移性疾病。
{"title":"Rapid Life-Saving Response to Anti-PD-1 in a Solid Organ Transplant Recipient With Metastatic Cutaneous Squamous Cell Carcinoma: A Case Report and Review.","authors":"John P Antonelli, Myiah Quach, Aparna Mahajan, Jennifer Pleva, Vincent T Ma","doi":"10.1097/CJI.0000000000000514","DOIUrl":"10.1097/CJI.0000000000000514","url":null,"abstract":"<p><strong>Summary: </strong>Anti-programmed cell death protein 1 (PD-1) therapy is considered effective in the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma but the use of these agents in solid organ transplant recipients (SOTRs) is often taken with caution. While anti-tumor effects without graft rejection have been reported, studies have shown high rates of fatal graft rejection with immune checkpoint therapy. In this case report, we present an SOTR patient with life-threatening, acute hypoxic respiratory failure due to rapidly progressive metastatic cutaneous squamous cell carcinoma with lung and pleural involvement. Modification of their immunosuppressive regimen and treatment with front-line anti-PD-1 inhibitor, pembrolizumab, led to rapid clinical response with near complete resolution of metastatic pulmonary disease and no long-term evidence of graft rejection. Our case report shows that front-line treatment with PD-1 inhibitors can be safely administered in SOTR patients with rapid metastatic disease control.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"216-219"},"PeriodicalIF":3.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study. 体外光子疗法作为免疫相关不良事件的一种治疗方案:两个病例报告和一项前瞻性研究。
IF 3.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-14 DOI: 10.1097/CJI.0000000000000510
Theresa Ruf, Farnaz Rahimi, David Anz, Amanda Tufman, Suzanna Salzer, Sarah Zierold, Dirk Tomsitz, Lars E French, Lucie Heinzerling

The wide use of immune checkpoint inhibitors has increased the frequency of immune-related adverse events (irAEs). While many are managed with corticosteroids or hormone substitution, up to 14.9% of irAEs are steroid-refractory or steroid-dependent and thus require second-line treatment. These should reduce irAE-related morbidity and mortality and induce a few side effects of their own while maintaining the antitumor response. There is little comparative data on second-line therapies for irAEs. Two cases of irAEs could not be sufficiently managed with corticosteroids and subsequently received treatment with extracorporeal photopheresis (ECP), including one patient with immune-related erosive oral lichen planus and one patient with immune-related colitis. In both cases, the irAE resolved with ECP in combination with immunosuppressive drugs, that is 4 weeks and 10 weeks after the start of ECP, respectively. To investigate this approach, a prospective clinical study that compares ECP and other second-line therapies for the treatment of steroid-refractory and steroid-dependent irAEs with regard to immunophenotype and therapy response has been designed. ECP could be a treatment option for steroid-refractory and steroid-dependent irAEs, given its good safety profile and lack of adverse effects on antitumor response. Comparative prospective studies are needed to generate an evidence base.

免疫检查点抑制剂的广泛使用增加了免疫相关不良事件(irAEs)的发生频率。虽然许多不良反应可通过皮质类固醇或激素替代治疗来控制,但高达 14.9% 的 irAEs 是类固醇难治性或类固醇依赖性的,因此需要二线治疗。这些治疗应能降低与虹膜AE相关的发病率和死亡率,并在维持抗肿瘤反应的同时产生一些自身的副作用。关于虹膜睫状体异常二线疗法的比较数据很少。有两例虹膜睫状体异常无法通过皮质类固醇得到充分控制,随后接受了体外光动力疗法(ECP)治疗,其中包括一名免疫相关侵蚀性口腔扁平苔藓患者和一名免疫相关结肠炎患者。在这两例患者中,ECP与免疫抑制剂联合使用后,虹膜急性睫状体炎分别在ECP开始4周和10周后得到缓解。为了研究这种方法,我们设计了一项前瞻性临床研究,对 ECP 和其他二线疗法治疗类固醇难治性和类固醇依赖性虹膜急性结肠炎的免疫表型和治疗反应进行比较。ECP 具有良好的安全性,且对抗肿瘤反应无不良影响,因此可作为类固醇难治性和类固醇依赖性虹膜异位症的治疗选择。需要进行前瞻性比较研究,以形成证据基础。
{"title":"Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study.","authors":"Theresa Ruf, Farnaz Rahimi, David Anz, Amanda Tufman, Suzanna Salzer, Sarah Zierold, Dirk Tomsitz, Lars E French, Lucie Heinzerling","doi":"10.1097/CJI.0000000000000510","DOIUrl":"10.1097/CJI.0000000000000510","url":null,"abstract":"<p><p>The wide use of immune checkpoint inhibitors has increased the frequency of immune-related adverse events (irAEs). While many are managed with corticosteroids or hormone substitution, up to 14.9% of irAEs are steroid-refractory or steroid-dependent and thus require second-line treatment. These should reduce irAE-related morbidity and mortality and induce a few side effects of their own while maintaining the antitumor response. There is little comparative data on second-line therapies for irAEs. Two cases of irAEs could not be sufficiently managed with corticosteroids and subsequently received treatment with extracorporeal photopheresis (ECP), including one patient with immune-related erosive oral lichen planus and one patient with immune-related colitis. In both cases, the irAE resolved with ECP in combination with immunosuppressive drugs, that is 4 weeks and 10 weeks after the start of ECP, respectively. To investigate this approach, a prospective clinical study that compares ECP and other second-line therapies for the treatment of steroid-refractory and steroid-dependent irAEs with regard to immunophenotype and therapy response has been designed. ECP could be a treatment option for steroid-refractory and steroid-dependent irAEs, given its good safety profile and lack of adverse effects on antitumor response. Comparative prospective studies are needed to generate an evidence base.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"227-231"},"PeriodicalIF":3.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. CTLA-4单核苷酸多态性对晚期黑色素瘤患者接受含伊匹单抗治疗方案毒性的影响
IF 3.9 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-06-01 Epub Date: 2024-02-06 DOI: 10.1097/CJI.0000000000000506
Karlijn de Joode, Alfonso Rojas Mora, Ron H N van Schaik, Alfred Zippelius, Astrid van der Veldt, Camille Léa Gerard, Heinz Läubli, Olivier Michielin, Roger von Moos, Markus Joerger, Mitchell P Levesque, Stefanie Aeppli, Johanna Mangana, Cristina Mangas, Nadine Trost, Stefan Meyer, Sandra Leoni Parvex, Ron Mathijssen, Yannis Metaxas

Single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, an inhibitor of T-cell priming, are associated with auto and alloimmunity. Studies implied a role for these SNPs as surrogate markers for immunotherapy-outcome in patients with melanoma. However, no predictive SNPs are defined to date. We analyzed different CTLA-4 SNPs in a large multicenter cohort of patients with ipilimumab-treated melanoma and investigated possible correlations with treatment-related outcomes. Archival blood and/or tumor tissue samples were collected from 361 patients with advanced-stage ipilimumab-treated (±nivolumab) in 6 Swiss and Dutch hospitals. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry based DNA genotyping was performed for 10 different CTLA-4 SNPs: 49A>G, CT60G>A, Jo27T>C, Jo30G>A, Jo31G>T, -658C>T, -1722T>C, -1661A>G, 318C>T, and C>T rs1863800. Associations between different allele genotypes and occurrence of grade ≥3 adverse events (AEs) and survival were tested using univariable logistic regressions or Cox proportional hazard models. 262/361 (73%) patients could be analyzed; 65% of those were males, the median age was 58 years, 39% showed a partial or complete response, and 65% had ≥1 AEs. A TT-genotype of -1722T>C SNP was significantly associated with a lower incidence of grade ≥3 AEs ( P = 0.049), whereas the GG-genotype of CT60G>A correlated with a higher incidence of grade ≥3 AEs ( P = 0.026). The TT-genotype of Jo27T>C SNP ( P = 0.056) and GG-genotype of Jo31G>T ( P = 0.046) were associated with overall survival. CTLA-4 SNPs might predict treatment-related outcomes in patients with melanoma receiving ipilimumab. Confirmatory studies are needed to fully exploit those findings as predictive biomarkers for ipilimumab AEs.

细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4)是一种 T 细胞启动抑制因子,其基因中的单核苷酸多态性(SNPs)与自身免疫和异体免疫有关。研究表明,这些 SNPs 可作为黑色素瘤患者免疫疗法结果的替代标记。然而,迄今为止还没有确定具有预测作用的 SNPs。我们分析了伊匹单抗治疗的黑色素瘤患者大型多中心队列中的不同 CTLA-4 SNPs,并研究了它们与治疗相关结果之间可能存在的关联。在瑞士和荷兰的6家医院收集了361名接受过ipilimumab治疗(±nivolumab)的晚期患者的存档血液和/或肿瘤组织样本。对10个不同的CTLA-4 SNPs进行了基于基质辅助激光解吸/电离飞行时间质谱的DNA基因分型:49A>G、CT60G>A、Jo27T>C、Jo30G>A、Jo31G>T、-658C>T、-1722T>C、-1661A>G、318C>T和C>T rs1863800。采用单变量逻辑回归或 Cox 比例危险模型检验了不同等位基因基因型与≥3 级不良事件(AEs)发生率和生存率之间的关系。262/361(73%)名患者接受了分析;其中65%为男性,中位年龄为58岁,39%的患者出现了部分或完全应答,65%的患者出现了≥1级不良反应。-1722T>C SNP的TT基因型与较低的≥3级AEs发生率显著相关(P = 0.049),而CT60G>A的GG基因型与较高的≥3级AEs发生率相关(P = 0.026)。Jo27T>C SNP的TT基因型(P = 0.056)和Jo31G>T的GG基因型(P = 0.046)与总生存率相关。CTLA-4 SNPs可预测接受伊匹单抗治疗的黑色素瘤患者的治疗相关结果。要充分利用这些发现作为伊匹单抗AEs的预测性生物标志物,还需要进行确证研究。
{"title":"Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.","authors":"Karlijn de Joode, Alfonso Rojas Mora, Ron H N van Schaik, Alfred Zippelius, Astrid van der Veldt, Camille Léa Gerard, Heinz Läubli, Olivier Michielin, Roger von Moos, Markus Joerger, Mitchell P Levesque, Stefanie Aeppli, Johanna Mangana, Cristina Mangas, Nadine Trost, Stefan Meyer, Sandra Leoni Parvex, Ron Mathijssen, Yannis Metaxas","doi":"10.1097/CJI.0000000000000506","DOIUrl":"10.1097/CJI.0000000000000506","url":null,"abstract":"<p><p>Single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, an inhibitor of T-cell priming, are associated with auto and alloimmunity. Studies implied a role for these SNPs as surrogate markers for immunotherapy-outcome in patients with melanoma. However, no predictive SNPs are defined to date. We analyzed different CTLA-4 SNPs in a large multicenter cohort of patients with ipilimumab-treated melanoma and investigated possible correlations with treatment-related outcomes. Archival blood and/or tumor tissue samples were collected from 361 patients with advanced-stage ipilimumab-treated (±nivolumab) in 6 Swiss and Dutch hospitals. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry based DNA genotyping was performed for 10 different CTLA-4 SNPs: 49A>G, CT60G>A, Jo27T>C, Jo30G>A, Jo31G>T, -658C>T, -1722T>C, -1661A>G, 318C>T, and C>T rs1863800. Associations between different allele genotypes and occurrence of grade ≥3 adverse events (AEs) and survival were tested using univariable logistic regressions or Cox proportional hazard models. 262/361 (73%) patients could be analyzed; 65% of those were males, the median age was 58 years, 39% showed a partial or complete response, and 65% had ≥1 AEs. A TT-genotype of -1722T>C SNP was significantly associated with a lower incidence of grade ≥3 AEs ( P = 0.049), whereas the GG-genotype of CT60G>A correlated with a higher incidence of grade ≥3 AEs ( P = 0.026). The TT-genotype of Jo27T>C SNP ( P = 0.056) and GG-genotype of Jo31G>T ( P = 0.046) were associated with overall survival. CTLA-4 SNPs might predict treatment-related outcomes in patients with melanoma receiving ipilimumab. Confirmatory studies are needed to fully exploit those findings as predictive biomarkers for ipilimumab AEs.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"190-194"},"PeriodicalIF":3.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139692022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma. PD-1抑制剂对手术切除的III/IV期口腔黑色素瘤患者的辅助治疗效果。
IF 3.9 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-11 DOI: 10.1097/CJI.0000000000000508
Haci Arak, Suna Erkiliç, Şendağ Yaslikaya, Eda Eylemer Mocan, Gökmen Aktaş, Melek Özdemir, Hüseyin Salih Semiz, Saadettin Kiliçkap, Faruk Recep Özalp, Özlem Nuray Sever, Goncagül Akdağ, Ahmet Burak Ağaoğlu, Melike Özçelik, Murat Sari, Murat Arcagök, Hicran Anik, Şaziye Burçak Yayla, Nadiye Sever, Fatma Pinar Açar, İsmail Bayrakçi, Serdar Turhal, Murat Ayhan, Tülay Kuş

Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters ( P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents ( P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies.

我们的目的是评估程序性细胞死亡蛋白-1(PD-1)抑制剂的辅助疗效,并比较其他辅助疗法对手术切除的III期或IV期尖锐湿疣患者的疗效。本研究是一项多中心回顾性分析。我们纳入了114名在过去10年内接受过手术的III期或IV期口角恶性黑色素瘤患者。我们分析了程序性细胞死亡蛋白-1抑制剂辅助治疗对无病生存期(DFS)的影响。平均随访时间为 40 个月,期间有 69 例(59.5%)患者复发。其中,64人(56.1%)接受了全身辅助治疗。具体来说,48.4%的患者接受了抗PD-1治疗,29.7%的患者接受了干扰素治疗,14.1%的患者接受了替佐唑胺治疗,7.8%的患者接受了B-Raf原癌基因/介原激活蛋白激酶抑制剂治疗。接受辅助治疗的患者的中位生存期为24(10.9-37.2)个月,而未接受辅助治疗的患者的中位生存期为15(9.8-20.2)个月。DFS的多变量分析显示,接受辅助治疗和淋巴结转移分期是独立的重要参数(分别为P = 0.021和P = 0.018)。在DFS方面,程序性细胞死亡蛋白-1抑制剂治疗与其他辅助治疗之间没有统计学差异。在总生存期(OS)方面,接受辅助治疗的患者的中位OS为71(30.4-111.7)个月,而未接受辅助治疗的患者的中位OS为38(16.7-59.3;P = 0.023)个月。此外,不同辅助治疗药物的中位生存期也无明显差异(P = 0.122)。在我们的研究中,我们发现辅助治疗对接受治愈性手术的 III-IV 期盲灶黑色素瘤患者的 DFS 和 OS 均有积极影响。值得注意的是,我们发现抗PD-1疗法与其他辅助疗法之间没有明显差异。
{"title":"The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.","authors":"Haci Arak, Suna Erkiliç, Şendağ Yaslikaya, Eda Eylemer Mocan, Gökmen Aktaş, Melek Özdemir, Hüseyin Salih Semiz, Saadettin Kiliçkap, Faruk Recep Özalp, Özlem Nuray Sever, Goncagül Akdağ, Ahmet Burak Ağaoğlu, Melike Özçelik, Murat Sari, Murat Arcagök, Hicran Anik, Şaziye Burçak Yayla, Nadiye Sever, Fatma Pinar Açar, İsmail Bayrakçi, Serdar Turhal, Murat Ayhan, Tülay Kuş","doi":"10.1097/CJI.0000000000000508","DOIUrl":"10.1097/CJI.0000000000000508","url":null,"abstract":"<p><p>Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters ( P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents ( P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"182-189"},"PeriodicalIF":3.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque. 犬科猕猴T细胞激活双特异性药物细胞因子缓解策略的非临床研究
IF 3.9 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-06-01 Epub Date: 2024-04-02 DOI: 10.1097/CJI.0000000000000512
Cris Kamperschroer, Magali Guffroy, Amy Shen, Melba Dokmanovich, Makeida Stubbs, Lynn M O'Donnell

Summary: T-cell-directed cancer therapies such as T-cell-engaging bispecifics (TCBs) are commonly associated with cytokine release syndrome and associated clinical signs that can limit their tolerability and therapeutic benefit. Strategies for reducing cytokine release are therefore needed. Here, we report on studies performed in cynomolgus monkeys to test different approaches for mitigating cytokine release with TCBs. A "priming dose" as well as subcutaneous dosing reduced cytokine release compared with intravenous dosing but did not affect the intended T-cell response to the bispecific. As another strategy, cytokines or cytokine responses were blocked with an anti-IL-6 antibody, dexamethasone, or a JAK1/TYK2-selective inhibitor, and the effects on toxicity as well as T-cell responses to a TCB were evaluated. The JAK1/TYK2 inhibitor and dexamethasone prevented CRS-associated clinical signs on the day of TCB administration, but the anti-IL-6 had little effect. All interventions allowed for functional T-cell responses and expected damage to target-bearing tissues, but the JAK1/TYK2 inhibitor prevented the upregulation of activation markers on T cells, suggesting the potential for suppression of T-cell responses. Our results suggest that short-term prophylactic dexamethasone treatment may be an effective option for blocking cytokine responses without affecting desired T-cell responses to TCBs.

摘要:T细胞定向癌症疗法,如T细胞激活双特异性药物(TCBs),通常与细胞因子释放综合征和相关临床症状有关,这可能会限制其耐受性和治疗效果。因此需要减少细胞因子释放的策略。在此,我们报告了在眼镜猴身上进行的研究,这些研究测试了使用细胞因子抑制剂减少细胞因子释放的不同方法。与静脉注射相比,"启动剂量 "和皮下注射可减少细胞因子的释放,但不会影响T细胞对双特异性的预期反应。另一种策略是用抗 IL-6 抗体、地塞米松或 JAK1/TYK2 选择性抑制剂阻断细胞因子或细胞因子反应,并评估其对毒性以及 T 细胞对 TCB 反应的影响。JAK1/TYK2抑制剂和地塞米松能防止在注射TCB当天出现CRS相关临床症状,但抗IL-6的效果甚微。所有干预措施都能使T细胞产生功能性反应,并对靶组织造成预期损伤,但JAK1/TYK2抑制剂能阻止T细胞活化标志物的上调,这表明它有可能抑制T细胞反应。我们的研究结果表明,短期预防性地塞米松治疗可能是阻断细胞因子反应而不影响T细胞对TCB的预期反应的有效选择。
{"title":"Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque.","authors":"Cris Kamperschroer, Magali Guffroy, Amy Shen, Melba Dokmanovich, Makeida Stubbs, Lynn M O'Donnell","doi":"10.1097/CJI.0000000000000512","DOIUrl":"10.1097/CJI.0000000000000512","url":null,"abstract":"<p><strong>Summary: </strong>T-cell-directed cancer therapies such as T-cell-engaging bispecifics (TCBs) are commonly associated with cytokine release syndrome and associated clinical signs that can limit their tolerability and therapeutic benefit. Strategies for reducing cytokine release are therefore needed. Here, we report on studies performed in cynomolgus monkeys to test different approaches for mitigating cytokine release with TCBs. A \"priming dose\" as well as subcutaneous dosing reduced cytokine release compared with intravenous dosing but did not affect the intended T-cell response to the bispecific. As another strategy, cytokines or cytokine responses were blocked with an anti-IL-6 antibody, dexamethasone, or a JAK1/TYK2-selective inhibitor, and the effects on toxicity as well as T-cell responses to a TCB were evaluated. The JAK1/TYK2 inhibitor and dexamethasone prevented CRS-associated clinical signs on the day of TCB administration, but the anti-IL-6 had little effect. All interventions allowed for functional T-cell responses and expected damage to target-bearing tissues, but the JAK1/TYK2 inhibitor prevented the upregulation of activation markers on T cells, suggesting the potential for suppression of T-cell responses. Our results suggest that short-term prophylactic dexamethasone treatment may be an effective option for blocking cytokine responses without affecting desired T-cell responses to TCBs.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"160-171"},"PeriodicalIF":3.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis. 基于单细胞 RNA 序列分析的 TIGIT 阻断疗法重塑了肿瘤微环境
IF 3.9 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-28 DOI: 10.1097/CJI.0000000000000511
Yanyan Lang, Hao Huang, Hongwei Jiang, Shaoxian Wu, Yaping Chen, Bin Xu, Yingting Liu, Dawei Zhu, Xiao Zheng, Lujun Chen, Jingting Jiang

Summary: Immune checkpoint blockade therapy is a pivotal approach in treating malignant tumors. TIGIT has emerged as a focal point of interest among the diverse targets for tumor immunotherapy. Nonetheless, there is still a lack of comprehensive understanding regarding the immune microenvironment alterations following TIGIT blockade treatment. To bridge this knowledge gap, we performed single-cell sequencing on mice both before and after the administration of anti-TIGIT therapy. Our analysis revealed that TIGIT was predominantly expressed on T cells and natural killer (NK) cells. The blockade of TIGIT exhibited inhibitory effects on Treg cells by downregulating the expression of Foxp3 and reducing the secretion of immunosuppressive cytokines. In addition, TIGIT blockade facilitated the activation of NK cells, leading to an increase in cell numbers, and promoted cDC1 maturation through the secretion of XCL1 and Flt3L. This activation, in turn, stimulated the TCR signaling of CD8 + T cells, thereby enhancing their antitumor effect. Consequently, anti-TIGIT therapy demonstrated substantial potential for cancer immunotherapy. Our research provided novel insights into future therapeutic strategies targeting TIGIT for patients with cancer.

免疫检查点阻断疗法是治疗恶性肿瘤的关键方法。在肿瘤免疫疗法的各种靶点中,TIGIT已成为人们关注的焦点。然而,人们对TIGIT阻断治疗后免疫微环境的改变仍缺乏全面的了解。为了弥补这一知识空白,我们在小鼠接受抗TIGIT治疗前后对其进行了单细胞测序。我们的分析表明,TIGIT 主要在 T 细胞和自然杀伤(NK)细胞上表达。通过下调 Foxp3 的表达和减少免疫抑制细胞因子的分泌,阻断 TIGIT 对 Treg 细胞有抑制作用。此外,阻断 TIGIT 还能促进 NK 细胞的活化,使细胞数量增加,并通过分泌 XCL1 和 Flt3L 促进 cDC1 的成熟。这种活化反过来又刺激了 CD8+T 细胞的 TCR 信号转导,从而增强了它们的抗肿瘤效果。因此,抗TIGIT疗法在癌症免疫疗法中展现了巨大的潜力。我们的研究为未来针对癌症患者的TIGIT治疗策略提供了新的见解。
{"title":"TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis.","authors":"Yanyan Lang, Hao Huang, Hongwei Jiang, Shaoxian Wu, Yaping Chen, Bin Xu, Yingting Liu, Dawei Zhu, Xiao Zheng, Lujun Chen, Jingting Jiang","doi":"10.1097/CJI.0000000000000511","DOIUrl":"10.1097/CJI.0000000000000511","url":null,"abstract":"<p><strong>Summary: </strong>Immune checkpoint blockade therapy is a pivotal approach in treating malignant tumors. TIGIT has emerged as a focal point of interest among the diverse targets for tumor immunotherapy. Nonetheless, there is still a lack of comprehensive understanding regarding the immune microenvironment alterations following TIGIT blockade treatment. To bridge this knowledge gap, we performed single-cell sequencing on mice both before and after the administration of anti-TIGIT therapy. Our analysis revealed that TIGIT was predominantly expressed on T cells and natural killer (NK) cells. The blockade of TIGIT exhibited inhibitory effects on Treg cells by downregulating the expression of Foxp3 and reducing the secretion of immunosuppressive cytokines. In addition, TIGIT blockade facilitated the activation of NK cells, leading to an increase in cell numbers, and promoted cDC1 maturation through the secretion of XCL1 and Flt3L. This activation, in turn, stimulated the TCR signaling of CD8 + T cells, thereby enhancing their antitumor effect. Consequently, anti-TIGIT therapy demonstrated substantial potential for cancer immunotherapy. Our research provided novel insights into future therapeutic strategies targeting TIGIT for patients with cancer.</p>","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"172-181"},"PeriodicalIF":3.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Immunotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1